[1]郑佳露,郑金洲,顾 贤.藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究[J].陕西中医,2023,(8):1042-1046.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
　ZHENG Jialu,ZHENG Jinzhou,GU Xian.Observation on the therapeutic effect of Tenglong Buzhong decoction combined with chemotherapy on advanced colorectal cancer[J].,2023,(8):1042-1046.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.010]
点击复制

藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年8期
页码:
1042-1046
栏目:
临床研究
出版日期:
2023-08-05

文章信息/Info

Title:
Observation on the therapeutic effect of Tenglong Buzhong decoction combined with chemotherapy on advanced colorectal cancer
作者:
郑佳露; 郑金洲; 顾 贤
(上海中医药大学附属龙华医院肿瘤科,上海 200032)
Author(s):
ZHENG Jialu; ZHENG Jinzhou; GU Xian
(Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
关键词:
结直肠癌;  藤龙补中汤;  化疗;  癌因性疲乏;  炎症因子;  肿瘤标志物
Keywords:
Colorectal cancer;  Tenglong Buzhong decoction;  Chemotherapy;  Cancer related fatigue;  Inflammatory factors;  Tumor markers
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7369.2023.08.010
文献标志码:
A
摘要:
目的:探讨藤龙补中汤剂联合化疗对晚期结直肠癌的治疗效果。方法:选择晚期结直肠癌患者100例,随机分为两组,每组50例,对照组予以奥沙利铂联合卡倍他滨(XELOX)方案治疗; 中药组在化疗基础上加藤龙补中汤治疗。比较两组疗程结束后的实体瘤疗效,并比较两组治疗前后中医症候积分、卡氏功能评分(KPS)、简明疲乏量表(BFI)评分、炎症因子、肿瘤标志物、T细胞亚群及不良反应情况。结果:中药组治疗后中医症候积分、KPS评分、BFI评分、炎症因子、肿瘤标志物、T细胞亚群较治疗前明显改善,且中药组改善程度显著优于对照组(均P<0.05); 两组治疗期间不良反应分级比较差异有统计学意义(P<0.05); 中药组总有效率为44.00%,疾病控制率为80.00%; 对照组疗效总有效率为20.00%,疾病控制率为40.00%; 中药组总有效率和疾病控制率显著高于对照组(均P<0.05)。结论:藤龙补中汤剂联合化疗治疗晚期结直肠癌可提升疗效,改善癌因性疲乏症状和日常生活能力,降低炎症因子和肿瘤标志物水平,调节免疫功能,减少化疗不良反应。
Abstract:
Objective:To explore the therapeutic effect of Tenglong Buzhong decoction combined with chemotherapy on advanced colorectal cancer.Methods:100 patients with advanced colorectal cancer were randomly selected and divided into two groups,each group with 50 cases.The control group was treated with oxaliplatin+capecitabine(XELOX)regimen,the Chinese medicine group was treated with Tenglong Buzhong decoction on the basis of chemotherapy,and the efficiency of solid tumors after the end of the treatment courses were observed and compared between the two groups.The TCM symptom scores,KPS scores,BFI scores,inflammatory factors,tumor markers,T cell subsets,and toxic side effects were also compared before and after treatment.Results:After treatment,the TCM syndrome scores,KPS scores,BFI scores,inflammatory factors,tumor markers,and T cell subsets in the Chinese medicine group were significantly improved compared with those before treatment,and the improvement degree was significantly better than those in the control group(all P<0.05).There were significant differences in the classification of toxicity and side effects between the two groups by rank sum test(P<0.05).After the treatment,the total effective rate of the Chinese medicine group was 44.00%,and the disease control rate was 80.00%; The total effective rate of the control group was 20.00%,and the disease control rate was 40.00%; The total effective rate and disease control rate of Chinese medicine group were significantly higher than those of control group(all P<0.05).Conclusion:Tenglong Buzhong decoction combined with chemotherapy can improve the overall treatment efficiency of advanced colorectal cancer,improve cancer related fatigue symptoms and daily living ability,reduce the levels of inflammatory factors and tumor markers,regulate immune function,and reduce toxic and side effects of chemotherapy.

参考文献/References:

[1] 章玉玲,周 岳.结直肠癌患者血清循环肿瘤细胞、糖类抗原24-2、糖类抗原19-9水平及其与临床病理特征关系[J].陕西医学杂志,2022,51(3):322-324,329.
[2] Malki A,ElRuz RA,Gupta I,et al.Molecular mechanisms of colon cancer progression and metastasis:Recent insights and advancements[J].Int J Mol Sci,2021,22(1):130.
[3] 汪耔璇,李 烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究[J].陕西中医,2020,41(10):1414-1417.
[4] 国家卫生健康委员会.中国结直肠癌诊疗规范(2020版)[J].中华消化外科杂志,2020,19(6):563-594.
[5] 中华中医药学会.中医肛肠科常见病诊疗指南[M].北京:中国中医药出版社,2012:46-57.
[6] 国家食品药品监督管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:362.
[7] Terret C,Albrand G,Moncenix G,et al.Karnofsky performance scale(KPS)or physical performance test(PPT)that is the question[J].Critical Reviews in Oncology/Hematology,2011,77(2):142-147.
[8] Mendoza TR,Wang XS,Cleeland CS,et al.The rapid assessment of fatigue severity in cancer patients:Use of the brief fatigue inventory[J].Cancer,1999,85(5):1186-1196.
[9] Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0:Development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[10] Eisenhauer EA,Therasse P,Bogaerts J,et al.Newresponse evaluation criteria in solid tumours:Revised RECIST guide line(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[11] 刘 萍,骆学新.肠益方联合XELOX化疗方案对老年晚期结直肠癌患者近期疗效及对血清SDC2、SEPT9和免疫功能的影响[J].中国老年学杂志,2022,42(5):1085-1087.
[12] 陈锦萍,林鸿悦,曾 杨,等.结直肠癌患者菌群多样性变化与5-FU联合奥沙利铂化疗诱导的炎症反应的关系[J].中国微生态学杂志,2019,31(11):1289-1296.
[13] 戴玲玲,侯爱画,毛俊俊,等.肠道菌群失调与脾虚型结直肠癌之间关系的研究进展[J].世界中医,2017,12(8):1970-1973.
[14] 郝菁华.益肠散结方联合FOLFIRI方案治疗晚期结直肠癌(脾虚湿盛型)的临床研究[D].济南:山东中医药大学,2021.
[15] 李振前,杨梦春,刘戎惠,等.扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究[J].陕西中医,2022,43(8):1037-1040.
[16] 邹永红,徐 娇,李 静,等.健脾祛瘀方择时用药联合化疗治疗脾虚瘀毒型中晚期结直肠癌的临床疗效及对T淋巴细胞亚群的影响[J].河北中医,2022,44(6):968-972.
[17] 郑佳露,闫 霞,沈克平,等.藤梨根抗肿瘤作用及机制[J].中华中医药学刊,2017,35(10):2562-2564.
[18] 张妮娜,卜 平,朱海杭,等.半枝莲抑制肿瘤血管生成的作用及其机制研究[J].癌症,2005,24(12):1459-1463.
[19] 胡 兵,沈克平,史秀峰,等.蛇莓对人结肠癌RKO细胞失巢凋亡作用的实验研究[J].世界中西医结合杂志,2013,8(1):69-72.
[20] 闫 霞,郑佳露,沈克平,等.龙葵抗肿瘤作用及机制研究[J].世界中西医结合杂志,2017,12(8):1177-1180.
[21] 李 淼,王双双,郑佳露,等.藤龙补中汤对SW620大肠癌转移和Wnt/β-catenin通路蛋白表达的影响[J].中华中医药杂志,2022,37(7):4083-4085.
[22] 宝乐日,卢艳琳,蔡芸芸,等.藤龙补中汤维持治疗对大肠癌转移抑制作用的临床研究[J].中国中西医结合消化杂志,2022,30(7):505-507,513.
[23] 柯东平,毛俊倩,刘 琪,等.TRIM21调控人结直肠癌细胞增殖分子机制研究[J].陕西医学杂志,2019,48(6):691-695.
[24] Milasiene V,Stratilatovas E,Norkiene V.The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients[J].Medicina,2007,43(7):548-554.
[25] 毛竹君,祝利民,卢艳琳,等.中医健脾法配合FOLFOX化疗方案对结肠癌术后患者癌因性疲乏、Th1/Th2免疫应答平衡及周围神经病变的影响[J].现代中西医结合杂志,2017,26(36):4027-4030.
[26] 黄晓伟,王双双,郑佳露,等.藤龙补中汤对大肠癌荷瘤小鼠免疫功能的影响[J].河北中医,2022,44(9):1512-1514,1518.

相似文献/References:

[1]吴昭利,李成军,李仁廷,等.通麻汤联合穴位注射治疗结直肠癌奥沙利铂化疗相关外周神经毒性疗效研究*[J].陕西中医,2019,(9):1247.
　WU Zhaoli,LI Chengjun,LI Renting,et al.Clinical study on Tongma decoction combined with acupoint injection in the treatment of peripheral neurotoxicity related to oxaliplatin chemotherapy for colorectal cancer[J].,2019,(8):1247.
[2]林增海,陆 军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医,2021,(10):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
　LIN Zenghai,LU Jun,WANG Kaisong.Regulatory mechanism of quercetin on resistance and autophagy of 5-FU induced colorectal cancer SW480 cells[J].,2021,(8):1338.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.004]
[3]章玲艳,吴会晨,汪 飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医,2023,(8):1086.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]
　ZHANG Lingyan,WU Huichen,WANG Fei,et al.Effects of modified Shenling Baizhu powder on bone marrow suppression and immune function in patients with colorectal cancer after chemotherapy[J].,2023,(8):1086.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.020]
[4]张国星,李恩泽,温 泉,等.益气养荣汤对结直肠癌术后化疗患者骨髓抑制、Treg/Th17细胞、无进展生存期的影响[J].陕西中医,2024,(4):490.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.012]
[5]塔吉姑丽·吐逊,陈治宇,马琪琪,等.白头翁汤联合PD-1抑制剂对结肠癌小鼠免疫微环境的影响[J].陕西中医,2025,46(2):170.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.005]
　TAJIGULI Tuxun,CHEN Zhiyu,MA Qiqi,et al.Effect of Baitouweng decoction combined with PD-1 inhibitor on immune micro-environment of colon cancer mice[J].,2025,46(8):170.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.005]
[6]宁永波,罗珍莲,宋子豪,等.基于“亢火害物”探讨结直肠“炎-癌转化”及防治思路[J].陕西中医,2025,46(4):512.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.017]
　NING Yongbo,LUO Zhenlian,SONG Zihao,et al.The prevention and treatment of colorectal “inflammation cancer transformation” based on “raging inferno and injuring wu”[J].,2025,46(8):512.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.017]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81804014)
更新日期/Last Update: 2023-08-10